Onconetix (ONCO) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Traws Pharma is the larger company by market cap ($2.7 million vs $2.4 million), about 1.1 times the size. Traws Pharma converts more of its revenue into profit, with a net margin of 328.7% versus -1721.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCO | TRAW |
|---|---|---|
| Share price | $2.89 | $0.175 |
| Market cap | $2.37M | $2.69M |
| 1-day change | -8.54% | -23.91% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $4,509.80 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $815.37K | $2.79M |
| Revenue growth (YoY) | -67.70% | +1134.51% |
| Net income (latest FY) | $-14.03M | $9.17M |
| Gross margin | 77.62% | — |
| Operating margin | -2190.03% | -640.68% |
| Net margin | -1720.98% | 328.67% |
| 52-week high | $1,610.00 | $3.23 |
| 52-week low | $2.76 | $0.1698 |
| Distance from 52-week high | -99.82% | -94.58% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +471.43% |
| Average volume | 412.90K | 610.04K |
| Shares outstanding | 820.61K | 15.37M |
| Employees | 2 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Traws Pharma is more profitable, keeping 328.7 cents of every revenue dollar as net income versus -1721.0 cents for Onconetix.
- Traws Pharma grew revenue faster in its latest fiscal year (+1134.51% vs -67.70%).
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ONCO vs TRAW FAQ
Which is bigger, Onconetix or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.37M for Onconetix (ONCO).
Are Onconetix and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.